Observational Study on the Management of Patients With Non Small Cell Lung Cancer Adenocarcinoma
MUTACT
1 other identifier
observational
2,000
1 country
101
Brief Summary
The main objective of the study is to determine the proportion of patients with M + mutation status among patients with Non Small Cell Lung Cancer adenocarcinoma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2010
101 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 20, 2010
CompletedFirst Posted
Study publicly available on registry
July 22, 2010
CompletedStudy Start
First participant enrolled
September 1, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2012
CompletedSeptember 10, 2012
September 1, 2012
2 years
July 20, 2010
September 7, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The main objective of the study is to determine the proportion of patients with M + mutation status among patients with NSCLC adenocarcinoma
At baseline
Secondary Outcomes (3)
Describe the therapeutic management according to the mutational status (EGFR M +, EGFR M- and Mx).
12 months / At each visit
Describe the therapeutic management of patients with EGFR M +.
12 months / At each visit
Describe the clinical course of patients EGFR-M +, treated for first-line treatment, and then 2nd line treatment, until 31-AUG-2012
12 months / At each visit
Study Arms (1)
1
Eligibility Criteria
Patient with NSCLC adenocarcinoma confirmed by histologyPatient for whom a search for the mutational status of EGFR (EGFR-M +, M- or Mx) has been done or is being analyzed
You may qualify if:
- Patient with lung cancer (Non Small Cell Lung Cancer adenocarcinoma)
- Patient for whom a search for the mutational status of EGFR (EGFR-M +, M- or Mx) has been done or is being analyzed
You may not qualify if:
- Assessment of mutational status of EGFR is not done
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (101)
Research Site
Abbeville, France
Research Site
Aix-en-Provence, France
Research Site
Amilly, France
Research Site
Angers, France
Research Site
Antibes, France
Research Site
Arras, France
Research Site
Aulnay-sous-Bois, France
Research Site
Auxerre, France
Research Site
Bastia, France
Research Site
Bayonne, France
Research Site
Béthune, France
Research Site
Blois, France
Research Site
Bobigny, France
Research Site
Bois-Guillaume, France
Research Site
Bonneville, France
Research Site
Bordeaux, France
Research Site
Boulogne-sur-Mer, France
Research Site
Bourg-en-Bresse, France
Research Site
Brest, France
Research Site
Brive-la-Gaillarde, France
Research Site
Bron, France
Research Site
Caen, France
Research Site
Chalon-sur-Saône, France
Research Site
Chauny, France
Research Site
Clermont-Ferrand, France
Research Site
Colmar, France
Research Site
Compiègne, France
Research Site
Creil, France
Research Site
Créteil, France
Research Site
Dijon, France
Research Site
Douai, France
Research Site
Draguignan, France
Research Site
Fougères, France
Research Site
Gap, France
Research Site
Granville, France
Research Site
La Roche-sur-Yon, France
Research Site
La Rochelle, France
Research Site
La Seyne-sur-Mer, France
Research Site
La Source, France
Research Site
La Tronche, France
Research Site
Le Plessis-Robinson, France
Research Site
Lens, France
Research Site
Levallois-Perret, France
Research Site
Libourne, France
Research Site
Liévin, France
Research Site
Lille, France
Research Site
Limoges, France
Research Site
Longjumeau, France
Research Site
Lyon, France
Research Site
Mantes-la-Jolie, France
Research Site
Marseille, France
Research Site
Meaux, France
Research Site
Mont-de-Marsan, France
Research Site
Mont-Saint-Martin, France
Research Site
Montauban, France
Research Site
Montivilliers, France
Research Site
Montpellier, France
Research Site
Moulins, France
Research Site
Nevers, France
Research Site
Niort, France
Research Site
Nîmes, France
Research Site
Oloron-Sainte-Marie, France
Research Site
Paris, France
Research Site
Pau, France
Research Site
Pessac, France
Research Site
Pierre-Bénite, France
Research Site
Poitiers, France
Research Site
Pontivy, France
Research Site
Pontoise, France
Research Site
Pringy, France
Research Site
Privas, France
Research Site
Redon, France
Research Site
Reims, France
Research Site
Rennes, France
Research Site
Roanne, France
Research Site
Rouen, France
Research Site
Saint-Aubin-lès-Elbeuf, France
Research Site
Saint-Brieuc, France
Research Site
Saint-Denis, France
Research Site
Saint-Herblain, France
Research Site
Saint-Pierre-des-Corps, France
Research Site
Saint-Priest-en-Jarez, France
Research Site
Saint-Quentin, France
Research Site
Saintes, France
Research Site
Salouël, France
Research Site
Sarrebourg, France
Research Site
Soissons, France
Research Site
Ste Clotilde, France
Research Site
Ste Feyre, France
Research Site
Strasbourg, France
Research Site
Toulon, France
Research Site
Toulouse, France
Research Site
Tourcoing, France
Research Site
Tours, France
Research Site
Trappes, France
Research Site
Valence, France
Research Site
Vendôme, France
Research Site
Verdun, France
Research Site
Villejuif, France
Research Site
Villenave-d'Ornon, France
Research Site
Yerres, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Corrine Bernaud, Medical Director
AstraZeneca
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 20, 2010
First Posted
July 22, 2010
Study Start
September 1, 2010
Primary Completion
September 1, 2012
Study Completion
September 1, 2012
Last Updated
September 10, 2012
Record last verified: 2012-09